Stockholders approve reverse split up to 1:199, authorized shares to 500M, and new equity plan

Matinas BioPharma Holdings, Inc.

All five director nominees elected; advisory vote on executive compensation passes with 5.56M for, 0.11M against.
Reverse stock split authorized in range of 1-for-2 to 1-for-199 over two years; 6.94M for, 0.54M against.
Authorized common shares increased from 250M to 500M; 6.91M for, 0.57M against.
2025 Equity Incentive Plan approved with 5.39M for, 0.28M against, 1.81M broker non-votes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.